Salix Pharmaceuticals, Ltd. news

   Watch this stock
Showing stories 1 - 10 of about 94   

Articles published

SLXP 135.59 +3.68 (2.79%)
price chart
Salix Pharmaceuticals Announces 2Q2014 Financial Results Conference Call ...
RALEIGH, N.C., Jul 24, 2014 (BUSINESS WIRE) -- Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report second quarter 2014 financial results following the close of the U.S.
Related articles »  
Salix Pharmaceuticals: The Newest Inversion Play
On Tuesday evening, U.S.-based Salix Pharmaceuticals Ltd. announced plans to merge with a unit of Cosmo Technologies Ltd.'s and take up residence in Ireland for tax purposes.
Salix Pharmaceuticals Ltd. (SLXP) Is Losing Ground After Merger Agreement  RTT News
Salix Stock Plunges Following Merger News  Bidness Etc
Related articles »  
INVESTOR ALERT -- Salix Pharmaceuticals, Ltd.: The Law Offices of Vincent ...
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) ("Salix Pharmaceuticals") in connection with the sale of the Company to a subsidiary of Cosmo ...
Related articles »  
Deals of the day: Salix Pharma does tax inversion dance
Salix Pharmaceuticals Ltd. (Nasdaq: SLXP), a North Carolina-based drug company focused on gastrointestinal diseases, has agreed to merge with Cosmo Pharmaceuticals (SIX: COPN), an Italian rug-maker domiciled in Ireland.
Salix Pharmaceuticals, Ltd. (SLXP) Insiders Sell Stock In The Company
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP), saw four insiders lower their exposure to the company. William P. Forbes, the EVP of Research & Development & the company's CDO, sold 1,971 shares of common stock at an average of $123.35 per share; EVP ...
Salix Pharmaceutical: A Good Find In Specialty Pharma (SLXP)
Salix Pharmaceuticals stock surged on July 1 on news its drug XIFAXAN for IBS-D met a primary endpoint in Phase 3. Obviously, this is good news for Salix and its investors, as it paves the way for future FDA approval.
Will This Price Target Increase Help Salix Pharmaceuticals (SLXP) Stock Today?
Salix Pharmaceuticals Ltd. (SLXP) Stock Reaches A New High
Related articles »  
Salix Pharmaceuticals Ltd.: Salix Pharmaceuticals to Combine with Cosmo ...
RALEIGH, N.C. & LAINATE, Italy--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. ("Salix") (NASDAQ: SLXP) and Cosmo Pharmaceuticals S.p.
Unusual Social Activity Today Around Salix Pharmaceuticals (SLXP)
SALIX PHARMACEUTICALS LTD has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago.
Salix Pharmaceuticals Surges on Positive IBS Data
Salix Pharmaceuticals, Ltd.'s (SLXP - Analyst Report) shares jumped 13.51% after the company announced encouraging data from a phase III study on Xifaxan (rifaximin) 550 mg.
Salix successful in appeal of Relistor label expansion CRL
The FDA's Office of Drug Evaluation III notifies Salix Pharmaceuticals (NASDAQ:SLXP) that the data submitted in its sNDA for a label expansion for Relistor (methylnaltrexone bromide) is sufficient for approval.
Salix Pharmaceuticals Price Target Increased to $150.00 by Analysts at Brean ...  WKRB News
Salix Pharmaceuticals Receives �Outperform� Rating from Leerink Swann (SLXP)  Ticker Report
Related articles »